BridgeBio Oncology Therapeutics, Inc. Marketable Securities, Unrealized Gain (Loss)
BridgeBio Oncology Therapeutics, Inc. (BBOT) reported Marketable Securities, Unrealized Gain (Loss) of $22.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Other Income
us-gaap:MarketableSecuritiesUnrealizedGainLoss · last filed 2026-08-11
- BridgeBio Oncology Therapeutics, Inc. marketable securities, unrealized gain (loss) for the quarter ending 2026-06-30 was $22.00K.
- BridgeBio Oncology Therapeutics, Inc. marketable securities, unrealized gain (loss) for the quarter ending 2026-03-31 was -$997.00K.
- BridgeBio Oncology Therapeutics, Inc. marketable securities, unrealized gain (loss) for the quarter ending 2025-12-31 was -$20.00K.
- BridgeBio Oncology Therapeutics, Inc. marketable securities, unrealized gain (loss) for the quarter ending 2025-09-30 was -$15.00K, a 101.90% decline year-over-year.
| Period end | Marketable Securities, Unrealized Gain (Loss) 3 month | Marketable Securities, Unrealized Gain (Loss) 6 month | Marketable Securities, Unrealized Gain (Loss) 9 month | Marketable Securities, Unrealized Gain (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | $22.00K 10-Q · filed 2026-08-11 | -$975.00K 10-Q · filed 2026-08-11 | -$995.00K derived: sum of 3 quarters · filed 2026-08-11 | -$1.01M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$997.00K 10-Q · filed 2026-08-11 | -$1.02M derived: sum of 2 quarters · filed 2026-08-11 | -$1.03M derived: sum of 3 quarters · filed 2026-08-11 | -$1.17M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | -$20.00K derived: POS AM 12 month − 10-Q 9 month · filed 2026-04-30 | -$35.00K derived: sum of 2 quarters · filed 2026-04-30 | -$175.00K derived: sum of 3 quarters · filed 2026-08-11 | -$332.00K POS AM · filed 2026-04-30 |
| 2025-09-30 | -$15.00K 10-Q · filed 2025-11-12 | -$155.00K derived: sum of 2 quarters · filed 2026-08-11 | -$312.00K 10-Q · filed 2025-11-12 | -$694.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$140.00K 10-Q · filed 2026-08-11 | -$297.00K 10-Q · filed 2026-08-11 | -$679.00K derived: sum of 3 quarters · filed 2026-08-11 | $110.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$157.00K 10-Q · filed 2026-08-11 | -$539.00K derived: sum of 2 quarters · filed 2026-08-11 | $250.00K derived: sum of 3 quarters · filed 2026-08-11 | $191.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2024-12-31 | -$382.00K derived: POS AM 12 month − 10-Q 9 month · filed 2026-04-30 | $407.00K derived: sum of 2 quarters · filed 2026-04-30 | $348.00K derived: sum of 3 quarters · filed 2026-04-30 | $348.00K POS AM · filed 2026-04-30 |
| 2024-09-30 | $789.00K 10-Q · filed 2025-11-12 | $730.00K derived: sum of 2 quarters · filed 2025-11-12 | $730.00K 10-Q · filed 2025-11-12 | |
| 2024-06-30 | -$59.00K 10-Q · filed 2025-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |